Condition
JIA
Total Trials
7
Recruiting
0
Active
0
Completed
5
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 7 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
14%
1 trials in Phase 3/4
Results Transparency
20%
1 of 5 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (4)
P 4 (1)
Trial Status
Completed5
Not Yet Recruiting1
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 5 completed trials
Clinical Trials (7)
Showing 7 of 7 trials
NCT07775612Not ApplicableNot Yet Recruiting
Pain-Sleep in Rheumatic Disease
NCT03816397Phase 4Completed
Adalimumab in JIA-associated Uveitis Stopping Trial
NCT00783510Completed
Juvenile Idiopathic Arthritis (JIA) Registry
NCT06284616Not ApplicableCompletedPrimary
JASP-1 for Children Recently Diagnosed and Their Parents
NCT05603286Not ApplicableCompletedPrimary
Using Self-evaluation to Increase Visit Intervals in Juvenile Idiopathic Arthritis
NCT05688358UnknownPrimary
Serum Interleukin - 17A in Juvenile Idiopathic Arthritis
NCT04168034Not ApplicableCompletedPrimary
iParent2Parent Program for Parents of Children With Juvenile Idiopathic Arthritis
Showing all 7 trials